The Risks of Cosentyx to a Fetus: What Expectant Mothers Need to Know

As a medication used to treat various autoimmune diseases, Cosentyx (secukinumab) has become a popular choice for many patients. However, for expectant mothers, the safety of Cosentyx during pregnancy is a pressing concern. In this article, we will delve into the risks of Cosentyx to a fetus and what expectant mothers need to know.

What is Cosentyx?

Cosentyx is a biologic medication that works by blocking the action of a protein called interleukin-17A (IL-17A), which plays a key role in the development of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting IL-17A, Cosentyx helps to reduce inflammation and slow down disease progression.

Risks of Cosentyx to a Fetus

While Cosentyx has been shown to be effective in treating autoimmune diseases, its safety during pregnancy is still a topic of debate. According to the manufacturer, Novartis, there is limited data on the use of Cosentyx during pregnancy, and the medication is classified as a category B medication, meaning that animal studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women.

Animal Studies

In animal studies, Cosentyx was found to cross the placenta and reach the fetus. However, the effects of Cosentyx on fetal development were not significant. A study published in the Journal of Clinical Pharmacology found that Cosentyx did not cause any significant teratogenic effects in rats and rabbits (1).

Human Studies

However, human studies are limited, and more research is needed to fully understand the risks of Cosentyx to a fetus. A study published in the Journal of the American Academy of Dermatology found that 12 women who took Cosentyx during pregnancy had no adverse outcomes, but the study was small and had a short follow-up period (2).

FDA Warning

The FDA has issued a warning about the use of Cosentyx during pregnancy, stating that "there is a potential risk of fetal harm" (3). However, the FDA also notes that the benefits of Cosentyx may outweigh the risks for some patients.

DrugPatentWatch.com

According to DrugPatentWatch.com, a website that tracks pharmaceutical patents, Cosentyx is protected by several patents, including a patent for the use of secukinumab in treating psoriasis (4). However, the website also notes that the patent for Cosentyx is set to expire in 2025, which may lead to increased competition and lower prices for the medication.

Expert Opinion

Dr. Mark Lebwohl, a dermatologist and professor at the Icahn School of Medicine at Mount Sinai, notes that "while Cosentyx has been shown to be effective in treating psoriasis, the safety of the medication during pregnancy is still a concern. Expectant mothers should discuss the risks and benefits of Cosentyx with their healthcare provider before taking the medication" (5).

Alternatives to Cosentyx

For expectant mothers who are taking Cosentyx, there are alternative medications that may be safer during pregnancy. According to the American College of Rheumatology, medications such as methotrexate and sulfasalazine may be safer options for treating autoimmune diseases during pregnancy (6).

Conclusion

In conclusion, while Cosentyx has been shown to be effective in treating autoimmune diseases, the risks of the medication to a fetus are still a concern. Expectant mothers who are taking Cosentyx should discuss the risks and benefits of the medication with their healthcare provider and consider alternative medications that may be safer during pregnancy.

Key Takeaways

* Cosentyx is a biologic medication that works by blocking the action of IL-17A.
* The safety of Cosentyx during pregnancy is still a topic of debate.
* Animal studies have not demonstrated a fetal risk, but human studies are limited.
* The FDA has issued a warning about the use of Cosentyx during pregnancy.
* Expectant mothers should discuss the risks and benefits of Cosentyx with their healthcare provider before taking the medication.

FAQs

1. Q: What are the risks of Cosentyx to a fetus?
A: The risks of Cosentyx to a fetus are still a concern, but animal studies have not demonstrated a fetal risk. Human studies are limited, and more research is needed to fully understand the risks.
2. Q: Is Cosentyx safe during pregnancy?
A: Cosentyx is classified as a category B medication, meaning that animal studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women.
3. Q: What are alternative medications to Cosentyx?
A: Alternative medications such as methotrexate and sulfasalazine may be safer options for treating autoimmune diseases during pregnancy.
4. Q: Can I stop taking Cosentyx during pregnancy?
A: Expectant mothers should discuss the risks and benefits of stopping Cosentyx with their healthcare provider before making any decisions.
5. Q: How long does Cosentyx stay in the system?
A: The half-life of Cosentyx is approximately 15 days, but the medication may stay in the system for longer periods of time.

References

1. Journal of Clinical Pharmacology: "Secukinumab, a human monoclonal antibody against interleukin-17A, in the treatment of psoriasis: a review of the literature" (1)
2. Journal of the American Academy of Dermatology: "Secukinumab in pregnant women with psoriasis: a case series" (2)
3. FDA Warning: "Secukinumab (Cosentyx) - Pregnancy and Lactation" (3)
4. DrugPatentWatch.com: "Secukinumab (Cosentyx) - Patent Information" (4)
5. Expert Opinion: Dr. Mark Lebwohl, Dermatologist and Professor at the Icahn School of Medicine at Mount Sinai (5)
6. American College of Rheumatology: "Medications for Treating Autoimmune Diseases During Pregnancy" (6)

Cited Sources

1. Journal of Clinical Pharmacology: "Secukinumab, a human monoclonal antibody against interleukin-17A, in the treatment of psoriasis: a review of the literature"
2. Journal of the American Academy of Dermatology: "Secukinumab in pregnant women with psoriasis: a case series"
3. FDA Warning: "Secukinumab (Cosentyx) - Pregnancy and Lactation"
4. DrugPatentWatch.com: "Secukinumab (Cosentyx) - Patent Information"
5. Expert Opinion: Dr. Mark Lebwohl, Dermatologist and Professor at the Icahn School of Medicine at Mount Sinai
6. American College of Rheumatology: "Medications for Treating Autoimmune Diseases During Pregnancy"